Search results
Jennifer Lopez cancels This Is Me…Now The Tour, including Acrisure Arena stop
The Desert Sun· 4 days agoSinger Jennifer Lopez announced Friday that she is canceling her upcoming tour, This Is Me…Now The...
One of AbbVie's post-Humira hopefuls gets closer to clearing hurdle in Europe
Crain s Chicago Business· 4 days agoThe EMA Committee for Medicinal Products for Human Use is recommending approval of the drug for the treatment of adults with moderately to severely active ulcerative colitis ...
First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related...
Forrest City Times-Herald· 4 days agoJohnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients with locally advanced or metastatic ...
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with...
telegraphherald.com· 5 days agoThe positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy and safety of risankizumab in adults with moderately to severely
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following...
Digital Journal· 1 day ago“Bizaxofusp represents a promising novel approach for targeted delivery of a potent therapeutic payload in rGBM, a uniformly fatal form of brain cancer that does not have an approved standard ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 24 hours agoLate-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with ...
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis...
Benzinga· 14 hours agoIn heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer...
Morningstar· 4 days agoInvestigational chemotherapy-free regimen of RYBREVANT® plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark Phase 3 MARIPOSA ...
Bitcoin Price Prediction: BTC Soars to $67,900; Mixed US Inflation Data & Fed Rate Cut Hopes Fuel...
Cryptonews· 4 days agoBitcoin surges to $67,900 as investors react to mixed US inflation data and growing anticipation of a potential Federal Reserve rate cut.
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 6 days agoClinical Microbiology Market Worth $6.9 billion | MarketsandMarkets™ PR Newswire CHICAGO, May 29, 2024 CHICAGO, May 29, 2024 /PRNewswire/ -- Clinical Microbiology ...